Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN101 vs placebo and semaglutide in type 2 diabetes mellitus
CTR20240817Phase 2Completed
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Mar 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of MWN101 in type 2 diabetes mellitus (T2DM), sponsored by Shanghai Minwei Biotechnology Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
MWN101
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20240817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240817.